Business growth

Roche's ENSPRYNG is FDA approved. It is the only subcutaneous drug for adults with antibody-positive optical neurielitis spectrum disorder. It is a rare and lifelong disease that primarily damages the optic nerves and spinal cord, causing blindness, muscle weakness and paralysis. It will be on sale in the United States in two weeks.